Medicenna Therapeutics (OTCMKTS:MDNAF) Lowered to Hold Rating by Zacks Research

Zacks Research lowered shares of Medicenna Therapeutics (OTCMKTS:MDNAF) from a strong-buy rating to a hold rating in a research note released on Tuesday morning,Zacks.com reports.

Medicenna Therapeutics Stock Performance

MDNAF stock opened at $0.63 on Tuesday. Medicenna Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.43. The stock has a market capitalization of $52.55 million, a P/E ratio of -5.73 and a beta of 1.81.

Medicenna Therapeutics (OTCMKTS:MDNAF) last announced its earnings results on Thursday, February 12th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Key Headlines Impacting Medicenna Therapeutics

Here are the key news stories impacting Medicenna Therapeutics this week:

• Positive Sentiment: Medicenna announced it will participate in several upcoming conferences, increasing management and program visibility to investors and industry peers; this type of investor engagement can support demand for the stock. Medicenna Therapeutics Announces Participation in Upcoming Conferences
• Negative Sentiment: HC Wainwright cut multiple near‑term EPS estimates (Q4 2026, Q1–Q4 2027 and FY2026–FY2027) — the firm now expects wider losses in FY2026–FY2027 versus prior forecasts, signaling a weaker near‑term profitability outlook and raising the potential for further dilutive financing or slower financial progress. MarketBeat: MDNAF analyst updates
• Negative Sentiment: HC Wainwright also trimmed longer‑term estimates: FY2028 projections moved more negative (to about ($0.12) from a smaller loss previously) and FY2029 and FY2030 earnings forecasts were lowered (FY2029 reduced to $0.10; FY2030 to $0.23), indicating the bank expects a slower recovery to profitability than before — a factor that can cap upside until clinical or commercial milestones arrive. MarketBeat: MDNAF analyst updates

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.